Allergan licenses Polyphor's PEM drugs in $61M deal

10 November 2008

Privately-held Swiss firm Polyphor has licensed the rights to develop Protein Epitope Mimetics cytokine inhibitors for conditions and diseases of the eye to US drugmaker Allergan.

Under the terms of the deal, the firms will conduct a research program designed to identify compounds that are optimally suited for local delivery to the eye in combination with Allergan's proprietary drug-delivery systems. The US firm will progress compounds arising from the collaboration through clinical development.

Polyphor will receive an upfront payment of $7.0 million and is entitled to receive up to $61.0 million in R&D and first commercial sales milestones, plus royalties.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK